ArticleBritish journal of cancer2006
The oncolytic effect in vivo of reovirus on tumour cells that have survived reovirus cell killing in vitro.
Article in British journal of cancer, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 38 citations in OpenAlex.
- Oral reovirus reshapes the gut microbiome and enhances antitumor immunity in colon cancer.Nature communications · 2024Article
- The reovirus variant RP116 is oncolytic in immunocompetent models and generates reduced neutralizing antibodies to Type 3 Dearing.Molecular therapy. Oncology · 2024Article
- Article
- Analysis of PPI networks of transcriptomic expression identifies hub genes associated with Newcastle disease virus persistent infection in bladder cancer.Scientific reports · 2023Article
- Combination Therapy with Reovirus and ATM Inhibitor Enhances Cell Death and Virus Replication in Canine Melanoma.Molecular therapy oncolytics · 2019Article
- Oncolytic virotherapy for urological cancers.Nature reviews. Urology · 2016Review
- Oncolytic reovirus synergizes with chemotherapeutic agents to promote cell death in canine mammary gland tumor.Canadian journal of veterinary research = Revue canadienne de recherche veterinaire · 2016Article
- Naturally occurring reoviruses for human cancer therapy.BMB reports · 2015Review
- Viral persistence in colorectal cancer cells infected by Newcastle disease virus.Virology journal · 2014Article
- Chemotherapy and Oncolytic Virotherapy: Advanced Tactics in the War against Cancer.Frontiers in oncology · 2014Review
- Trial watch: Oncolytic viruses for cancer therapy.Oncoimmunology · 2013Article
- The combined effects of oncolytic reovirus plus Newcastle disease virus and reovirus plus parvovirus on U87 and U373 cells in vitro and in vivo.Journal of neuro-oncology · 2011Article
- Attenuated reovirus displays oncolysis with reduced host toxicity.British journal of cancer · 2011Article
- Oncolytic bluetongue viruses: promise, progress, and perspectives.Frontiers in microbiology · 2011Article
- Cancer research meets evolutionary biology.Evolutionary applications · 2009Article
- Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin.Cancer research · 2007Article
- Oncolytic viruses in cancer therapy.Cancer letters · 2007Review
- Proteolytic disassembly is a critical determinant for reovirus oncolysis.Molecular therapy : the journal of the American Society of Gene Therapy · 2007Article
- Viruses as anticancer drugs.Trends in pharmacological sciences · 2007Review
- Trial Watch:: Oncolytic viruses for cancer therapy.OncoimmunologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The use of oncolytic viruses has received considerable attention in recent years and many viruses have proved to be effective against a variety of cancer models and a few are currently being used in clinical trials. However, the possible emergence and outcome of virus-resistant tumour cells has not been addressed. We previously reported the effective use of reovirus against lymphoid malignancies, including the Burkitt's lymphoma cell line Raji. Here we isolated in vitro persistently infected (PI) Raji cells, and cells 'cured' of persistent reovirus infection ('cured' cells). Both PI and cured Raji cells resisted reovirus infection and cell killing in vitro. In vivo, the PI cells were non-tumorigenic in SCID mice, but cured cells regained the parental cells' ability to form tumours. Tumour xenografts from the cured cells, however, were highly susceptible to reovirus oncolysis in vivo. This susceptibility was due to the proteolytic environment within tumours that facilitates reovirus infection and cell killing. Our results show that persistent infection by reovirus impedes tumour development and that although PI cells cleared of reovirus are tumorigenic, they are killed upon rechallenge with reovirus. Both the PI and cured states are therefore not likely to be significant barriers to reovirus oncolytic therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.